QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel
- PMID: 22026519
- PMCID: PMC4078896
- DOI: 10.1080/10550887.2011.610710
QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel
Erratum in
- J Addict Dis. 2012 Jan;31(1):91. Haigney, Mark C P [added]
Abstract
In an effort to enhance patient safety in opioid treatment programs, the Substance Abuse and Mental Health Saervices Administration convened a multi-disciplinary Expert Panel on the Cardiac Effects of Methadone. Panel members (Appendix A) reviewed the literature, regulatory actions, professional guidances, and opioid treatment program experiences regarding adverse cardiac events associated with methadone. The Panel concluded that, to the extent possible, every opioid treatment program should have a universal Cardiac Risk Management Plan (incorporating clinical assessment, electrocardiogram assessment, risk stratification, and prevention of drug interactions) for all patients and should strongly consider patient-specific risk minimization strategies (such as careful patient monitoring, obtaining electrocardiograms as indicated by a particular patient's risk profile, and adjusting the methadone dose as needed) for patients with identified risk factors for adverse cardiac events. The Panel also suggested specific modifications to informed consent documents, patient education, staff education, and methadone protocols.
Conflict of interest statement
Consistent with requirements of the Accreditation Council on Continuing Medical Education (ACCME), members of the Expert Panel and project staff were asked to report any relevant financial relationships. The following Panel members, ex officio members, guests, and staff reported no known or potential conflicts of interest: Mr. Bowman, Dr. Campbell, Dr. Fan, Dr. Haigney, Dr. Kahn, Dr. Killip, Dr. Kreek, Mr. Lubran, Dr. Martin, Dr. Payte, Dr. Rappaport, Dr. Stimmel, Dr. Taylor, and Mrs. Wilford.
Dr. Gourevitch reported research support from Alkermes, Inc. Dr. Kotz reported honoraria paid to her spouse by Abbott Laboratories and Forrest Laboratories. Dr. Krantz reported conference support from Reckitt-Benckiser, Inc. Dr. McCarroll reported honoraria from Reckitt-Benckiser, Inc. Dr. Mehta reported honoraria from Medtronic and Boston Scientific. Dr. O’Keeffe reported consulting fees from Catalyst Pharmaceutical Partners, Inc. and Reckitt-Benckiser, Inc., and an ownership interest in Kingston Pharmaceuticals, Inc.
Figures
References
-
- Center for Substance Abuse Treatment (CSAT) Methadone-Associated Mortality: Report of a National Assessment, May 2003. Rockville, MD: CSAT, Substance Abuse and Mental Health Services Administration; 2004. [Accessed at http://www.csdp.org/research/methadone.samhsa204.pdf on February 16, 2011.]
-
- Center for Substance Abuse Treatment (CSAT) Methadone Mortality: A Reassessment – Report of the Meeting and Follow-up Activities, July 2007. Rockville, MD: CSAT, Substance Abuse and Mental Health Services Administration; 2007. pp. 32–36. [Accessed at http://www.dpt.samhsa.gov/pdf/Methadone_Report_10%2018%/2007_Brief%20w%2... on February 16, 2011.]
-
- Food and Drug Administration (FDA) Public Health Advisory: Methadone Use for Pain Control May Result in Death and Life-Threatening Changes in Breathing and Heart Beat. 2006 Nov 27; [Accessed at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety/SafetyInformati... on February 16, 2011.]
-
- Roxane Laboratories. Dolophine Hydrochloride CII (Methadone Hydrochloride Tablets, USP) Columbus OH 43216: [Accessed at http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/006134s0281lbl.pdf on February 16, 2011.]
-
- Thompson Reuters MICROMEDEX®. [Accessed at www.thomsonhc.com. February 22, 2011.]
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical